Aldeyra Therapeutics, Inc (NASDAQ:ALDX)’s stock price shot up 5.8% during mid-day trading on Tuesday . The company traded as high as $5.20 and last traded at $5.10, 407,551 shares were traded during trading. An increase of 14% from the average session volume of 358,750 shares. The stock had previously closed at $4.82.
A number of brokerages have recently issued reports on ALDX. Cantor Fitzgerald restated an “overweight” rating and set a $33.00 price objective on shares of Aldeyra Therapeutics in a report on Thursday, October 17th. Zacks Investment Research upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Finally, ValuEngine upgraded Aldeyra Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $24.19.
The company has a market cap of $134.72 million, a P/E ratio of -2.85 and a beta of 0.97. The business has a fifty day moving average price of $6.01 and a 200-day moving average price of $5.81. The company has a quick ratio of 6.36, a current ratio of 6.36 and a debt-to-equity ratio of 0.28.
Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.14). As a group, research analysts expect that Aldeyra Therapeutics, Inc will post -2.33 earnings per share for the current year.
In other Aldeyra Therapeutics news, Director Richard Douglas purchased 10,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average cost of $6.03 per share, for a total transaction of $60,300.00. Following the completion of the transaction, the director now owns 70,000 shares in the company, valued at $422,100. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Todd C. Brady purchased 14,288 shares of the company’s stock in a transaction dated Wednesday, September 18th. The stock was acquired at an average price of $5.91 per share, with a total value of $84,442.08. Following the completion of the transaction, the chief executive officer now owns 614,826 shares of the company’s stock, valued at approximately $3,633,621.66. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 46,378 shares of company stock valued at $272,681. 13.50% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Strs Ohio raised its position in shares of Aldeyra Therapeutics by 7.5% in the second quarter. Strs Ohio now owns 71,900 shares of the biotechnology company’s stock valued at $431,000 after buying an additional 5,000 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Aldeyra Therapeutics during the second quarter valued at approximately $30,000. Bank of New York Mellon Corp raised its position in Aldeyra Therapeutics by 7.7% during the second quarter. Bank of New York Mellon Corp now owns 75,353 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 5,406 shares in the last quarter. Algert Global LLC raised its position in Aldeyra Therapeutics by 28.6% during the second quarter. Algert Global LLC now owns 29,840 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 6,631 shares in the last quarter. Finally, Private Advisors LLC raised its position in Aldeyra Therapeutics by 21.8% during the second quarter. Private Advisors LLC now owns 40,270 shares of the biotechnology company’s stock valued at $242,000 after purchasing an additional 7,211 shares in the last quarter. Institutional investors own 60.34% of the company’s stock.
Aldeyra Therapeutics Company Profile (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
See Also: Management Fee
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.